December 2008 Oncology News International

How Will Gastrointestinal Cancer Standards of Care Change? An ESMO Recap

Phase 2 data showed no dose-limiting toxicities with EIK1001 plus pembrolizumab in patients with advanced non–small cell lung cancer.

Three GI cancer medical oncologists discuss the most significant abstracts in GI cancers from the 2025 ESMO Congress.

Nicholas James Hornstein, MD, PhD;Timothy Brown, MD;Udhayvir S. Grewal, MD

Lifileucel Confers Durable Responses in Pretreated Advanced NSCLC Type

Three GI cancer medical oncologists discuss the most significant abstracts in GI cancers from the 2025 ESMO Congress.

Improvements in safety were observed without compromising efficacy after non-myeloablative lymphodepletion was reduced in this NSCLC population.

What Were the Key Presentations at ESMO 2025? Oncology Experts Discuss

Improvements in safety were observed without compromising efficacy after non-myeloablative lymphodepletion was reduced in this NSCLC population.

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

Sara A. Hurvitz, MD;Xiuning Le, MD, PhD;Erica L. Mayer, MD, MPH

October 27th 2025

How Can Cancer Cachexia Be Treated? Molecular Subtypes May Be Key

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

Sick asian senior woman suffering from anorexia,bored with meal,eating less food or discomfort in swallowing,disease of Dysphagia,Old elderly patient having lack of appetite,nutrition and health care | © Satjawat - stock.adobe.com

Ariana Pelosci

Forming CUTNETs: A Joint Venture Between Surgery and Oncology in NETs

Cancer cachexia can be deadly, and due to AEs or the tumor itself, scientists are now looking at molecular subtypes to inform treatment decisions.

Considering historical trends of underpowered data in NET surgical studies, CUTNETs established a collaboration of surgical teams to better power research.

Novel TLR Coagonist Combo Shows Responses in Stage IV NSCLC

Considering historical trends of underpowered data in NET surgical studies, CUTNETs established a collaboration of surgical teams to better power research.

Related Content

Caroline Seymour

How Will Gastrointestinal Cancer Standards of Care Change? An ESMO Recap

Phase 2 data showed no dose-limiting toxicities with EIK1001 plus pembrolizumab in patients with advanced non–small cell lung cancer.

Nicholas James Hornstein, MD, PhD;Timothy Brown, MD;Udhayvir S. Grewal, MD

Lifileucel Confers Durable Responses in Pretreated Advanced NSCLC Type

Three GI cancer medical oncologists discuss the most significant abstracts in GI cancers from the 2025 ESMO Congress.

What Were the Key Presentations at ESMO 2025? Oncology Experts Discuss

Improvements in safety were observed without compromising efficacy after non-myeloablative lymphodepletion was reduced in this NSCLC population.

Sara A. Hurvitz, MD;Xiuning Le, MD, PhD;Erica L. Mayer, MD, MPH

October 27th 2025

How Can Cancer Cachexia Be Treated? Molecular Subtypes May Be Key

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

Ariana Pelosci

Forming CUTNETs: A Joint Venture Between Surgery and Oncology in NETs

Cancer cachexia can be deadly, and due to AEs or the tumor itself, scientists are now looking at molecular subtypes to inform treatment decisions.